Prepared for
MedTech
Hero Finding
A strong majority of prescribing physicians would switch a portion of their cardiac monitoring patients to the expanded-lead patch.
The adoption signal is unambiguous. Almost no respondents declined to switch any patients; a small minority were neutral. The remainder would switch a portion of their existing remote monitoring patients, with a mean switching intent in the mid-50% range and a similar median. Physicians anchored the value proposition on three capabilities: superior diagnostic accuracy through multi-lead data, enhanced arrhythmia differentiation, and ischemia or ST-segment evaluation that single-lead monitors cannot perform.
Majority
Would switch a portion of patients to the expanded-lead patch
Mid-50%
Mean patient share they would switch
High share
Agree the device increases diagnostic confidence
Two-thirds
Rate overall clinical value as very or extremely valuable
Study Design
N=55 prescribing physicians across the specialties that drive remote cardiac monitoring orders · AI-moderated quant + qual interviews · all active patch monitor prescribers.
The sample was structured to capture multiple prescribing specialties with different clinical use contexts, balanced across patch volume tiers and practice settings to surface both early adopter and late adopter signals.
Sample segmentation
General cardiology · 30
Acute / emergency · 14
Subspecialty cardiology · 11
Interview guide · core topics
- Initial reaction to the on-demand expanded-lead patch concept and perceived clinical utility
- Diagnostic confidence: would the device increase confidence in prescribing remote cardiac monitoring
- Use case value matrix: arrhythmia differentiation, ectopy localization, ischemia, conduction, QT interval
- Switching intent: portion of single-lead and multi-lead patch patients physicians would migrate
- Market expansion: would the device increase total monitoring volume and unlock new patient populations
- Symptomatic vs. algorithm-detected multi-lead capture: relative clinical value
- Adoption requirements: clinical evidence, reimbursement, workflow fit, training
Recruit criteria
- Currently practicing physician with five or more years in a remote-monitoring-prescribing specialty
- Active prescriber of remote cardiac monitors: extended Holter, single or multi-lead patch, MCT, or implantable loop
- Prescribes a minimum of 30 patch monitors per year
- Decision-maker or significant influencer on remote monitoring technology selection
Key Findings
What the research surfaced for adoption strategy.
Six signals defined the commercial roadmap: where the device wins on clinical value, who adopts first, and what the market entry plan needs to address.
Majority
Would switch a portion of cardiac monitoring patients
Mid-50%
Mean patient share they would switch
Majority
Would prescribe to additional patient populations
Acute lead
Acute-setting physicians lead overall switching intent
Two-thirds
Cite reimbursement clarity as required for adoption
14 days
Kickoff to final report
01
Switching intent is broad and durable across the full sample.
Almost no physicians declined to switch any patients. A small minority were neutral. The remainder would migrate a portion of their existing remote monitoring patients, with a mean switching intent in the mid-50% range and a similar median. A meaningful share strongly agreed they would switch. The result is consistent across the prescribing specialties and does not concentrate in a narrow super-user cohort.
02
Ectopy localization and arrhythmia differentiation are the highest-value diagnostic gaps.
When asked to rate the additional value of multi-lead capture across diagnostic use cases, ectopy and arrhythmia origin localization scored highest, followed by arrhythmia differentiation and ischemia or ST-segment changes. A majority of physicians named AFib vs. AFlutter differentiation and SVT vs. VT with aberrancy as the top clinical scenarios. These are high-stakes, ablation-relevant decisions where single-lead recordings leave physicians with diagnostic ambiguity.
03
Ischemia evaluation opens a category single-lead monitors cannot serve.
Among the majority of physicians who said they would expand monitoring to new patient populations, ischemia patients are the most frequently cited new target. Single-lead monitors cannot assess ST-segment changes, so chest pain and ischemia evaluation in the outpatient setting is a category that prescribing physicians describe as currently unserved. A meaningful share of respondents cited concrete patient cases where multi-lead capture would have changed their monitoring approach for ischemia or ST-segment evaluation.
04
Acute-setting physicians lead the super-adopter segment, with the highest switching intent and projected volume growth.
Acute-setting physicians index higher than the broader cardiology cohort across every adoption metric. They project a higher patient share to switch and a larger increase in total monitoring volume. They also over-index on syncope, intermittent symptoms, and post-discharge monitoring use cases. The acute-to-outpatient handoff is a distinct adoption beachhead.
05
The device expands the monitoring market beyond simple substitution.
Adoption is not zero-sum substitution. A majority of physicians say the device would expand their prescribing to patients they do not monitor today, with a meaningful mean anticipated volume increase. Combined with the switching intent data, the implied net category volume lift is in the low double digits. The new patient populations skew toward ischemia, syncope, and patients with prior nondiagnostic monitoring results.
06
Reimbursement clarity is the gating adoption requirement.
When asked what they need to see to feel comfortable prescribing, physicians named reimbursement clarity first, followed by peer-reviewed clinical evidence, workflow and EMR integration, and training and patient education. Reimbursement is the largest single adoption gate. Clinical evidence requirements are achievable and well-scoped: physicians want performance equivalency or superiority data and clear payer pathways before prescribing.
“Multi-lead capture would mean much more sensitivity and specificity and, in particular, differentiating between atrial and ventricular rhythms.”— Cardiologist, Hospital System
Crosstab · Diagnostic Value by Use Case
Ectopy localization and arrhythmia differentiation lead the diagnostic value matrix; QT monitoring trails.
Indexed share of physicians rating each diagnostic use case as essential, high, or moderate additional value vs. a single-lead or 3-lead patch monitor. The pattern points the early commercial messaging toward arrhythmia and ischemia, with conduction and QT as secondary positioning. Indexed to peak = 100.
| Essential or high (index) | Essential, high, or moderate (index) | |
|---|---|---|
| Ectopy / arrhythmia origin localization | 100 | 100 |
| Arrhythmia differentiation | 94 | 92 |
| Ischemia / ST-segment changes | 84 | 85 |
| Conduction abnormalities (BBB) | 73 | 85 |
| QT interval monitoring | 56 | 75 |
N=55 prescribing physiciansTop scenarios: AFib vs. AFlutter, SVT vs. VT with aberrancyMulti-lead also valued for PVC morphology and ablation planning
Voice of Customer
How prescribing physicians describe the expanded-lead patch in their own words.
Verbatims from AI-moderated interviews across the prescribing specialties, selected to represent the range of views on diagnostic value, adoption rationale, and workflow concerns.
Diagnostic Confidence · Sensitivity
“More leads would mean much more sensitivity and specificity and, in particular, differentiating between atrial and ventricular rhythms.”
— Cardiologist, Hospital System
Ischemia · Single-Lead Gap
“If someone has chest pain and they have a single-lead EKG monitor, you can't make any decisions or diagnosis from that. With multi-lead capture, you can rule out any level of ischemia, whether it be elevation, depression, or T-wave inversions in a specific distribution.”
— Cardiologist, Hospital System
Complex Arrhythmia · Gold Standard
“For complex arrhythmia patients, multi-lead capability needs to be the gold standard. The single lead is wholly inadequate.”
— Cardiologist, Academic
Switching Intent · Unambiguous
“I would switch all of them, to be honest, because I see no reason not to. It gives you so much more information.”
— Acute-care physician, Community
Market Expansion · New Use Cases
“This would actually pave a way for a new use case and service line for our hospital.”
— Cardiologist, Academic
Workflow · EMR Integration
“Reporting should integrate with the EMR, and there should not be a lot of prior authorization hassle.”
— Cardiologist, Community
Counter-intuitive
Acute-setting physicians are the strongest adopter segment, ahead of general and subspecialty cardiology.
The prevailing assumption was that subspecialty cardiologists, who run the most arrhythmia-complex cases, would be the lead adopter cohort. The data points elsewhere. Acute-setting physicians show the highest switching intent, the largest projected volume growth, and the strongest concentration of new use cases the device unlocks: syncope, intermittent symptoms, and post-discharge monitoring. They treat the device as a tool that closes the loop on patients they currently send home with diagnostic ambiguity. The implication for the launch sequence is direct: acute-care is a higher-yield first-call segment than the originally assumed subspecialty-led adoption path.
Strategic Implications
Three commercial moves from the research.
What the research team took into commercial planning, grounded in switching intent, segment heterogeneity, and the adoption requirement framework.
01
Lead with arrhythmia differentiation and ischemia evaluation in clinical messaging.
These are the two highest-value diagnostic use cases and the ones where physicians describe single-lead monitoring as fundamentally inadequate. AFib vs. AFlutter, SVT vs. VT with aberrancy, and chest pain with suspected ischemia are the lead clinical scenarios that should anchor the product positioning, sales narrative, and KOL evidence strategy.
02
Sequence the launch with the acute-care setting as the beachhead, then expand to general cardiology and subspecialty cardiology.
Acute-setting physicians show the strongest switching intent and projected volume growth, with strong over-indexing on use cases the device uniquely addresses (syncope, intermittent symptoms, post-discharge handoff). The launch playbook should prioritize acute-care-specific evidence development, acute-to-outpatient handoff workflows, and acute-setting champion programs before scaling to the broader cardiology audience.
03
Resolve reimbursement clarity before broad commercial activation.
Reimbursement is the largest adoption gate (cited by roughly two-thirds). Payer pathway documentation, coding clarity, and coverage confirmation are prerequisites to sales velocity, not post-launch optimizations. Clinical evidence and workflow integration follow as the secondary adoption requirements, addressable through peer-reviewed publication and EMR partnership investments.
Success criteria · 12 months
- Acute-care-specific evidence package and champion program live before broad cardiology activation
- Reimbursement pathway documented with coverage confirmation across top commercial payers
- EMR integration validated for the highest-volume cardiology and acute-care customer systems
- Peer-reviewed clinical evidence published demonstrating performance vs. single-lead and 3-lead comparators
Risk register
| Reimbursement pathway ambiguity | HIGH |
| Patient activation and compliance burden | MED |
| EMR integration friction at scale | MED |
| Single-lead competitor response | MED |
| Clinical evidence timeline slippage | LOW |